Berberine Evaluated for Liver Fat
Six-month randomized trial finds no reduction in visceral or hepatic fat in patients with obesity and MASLD
-
By
-
Jo Cavallo
-
February 12, 2026
-
Clinical Scorecard: Berberine Evaluated for Liver Fat
At a Glance
| Category | Detail |
|---|
| Condition | Metabolic dysfunction-associated steatotic liver disease (MASLD) |
| Key Mechanisms | Berberine's effects on lipid levels and inflammatory markers |
| Target Population | Patients with obesity and MASLD without diabetes |
| Care Setting | Randomized clinical trial across 11 hospitals in China |
Key Highlights
- No reduction in visceral adipose tissue or liver fat content after 6 months
- Berberine associated with reductions in LDL cholesterol and hs-CRP
- Similar incidence of adverse events in berberine and placebo groups
- Exploratory findings suggest benefits in patients with higher baseline hs-CRP
- Berberine demonstrated an excellent safety profile
Guideline-Based Recommendations
Diagnosis
- Assess liver fat content and visceral adipose tissue in patients with obesity and MASLD
Management
- Consider lifestyle interventions alongside any pharmacological treatments
Monitoring & Follow-up
- Monitor lipid levels and inflammatory markers such as hs-CRP
Risks
- Evaluate for potential adverse events, though berberine shows a favorable safety profile
Patient & Prescribing Data
337 patients with obesity and MASLD, diabetes-free
1 g daily berberine did not significantly affect liver fat or VAT
Clinical Best Practices
- Incorporate lifestyle modifications in treatment plans for MASLD
- Monitor lipid profiles and inflammatory markers during treatment
References
